Payload Information
General Information of This Payload
| Payload ID | PAY0VGSXI |
|||||
|---|---|---|---|---|---|---|
| Name | CN119343152A Trastuzumab-Example5 Payload |
|||||
| Synonyms |
CN119343152A Trastuzumab-Example5 Payload
Click to Show/Hide
|
|||||
| Target | Microtubule (MT) | |||||
| Structure |
|
|||||
| Formula | C40H65N5O8 |
|||||
| Isosmiles | C[C@H]([C@@H](N(C)C([C@@H](NC([C@@H]1CCCCN1C)=O)C(C)C)=O)[C@H](OC)CC(N2CCC[C@H]2[C@H](OC)[C@H](C(N[C@H](C(O)=O)CC3=CC=CC=C3)=O)C)=O)CC |
|||||
| InChI |
InChI=1S/C40H65N5O8/c1-10-26(4)35(44(7)39(49)34(25(2)3)42-38(48)31-19-14-15-21-43(31)6)32(52-8)24-33(46)45-22-16-20-30(45)36(53-9)27(5)37(47)41-29(40(50)51)23-28-17-12-11-13-18-28/h11-13,17-18,25-27,29-32,34-36H,10,14-16,19-24H2,1-9H3,(H,41,47)(H,42,48)(H,50,51)/t26-,27+,29-,30-,31-,32+,34-,35+,36+/m0/s1
|
|||||
| InChIKey |
LAYVNPLGOZNFSK-FZLRHWLVSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
743.987 |
Polar area |
157.82 |
||
Complexity |
1306.503054 |
xlogp Value |
3.3439 |
|||
Heavy Count |
53 |
Rot Bonds |
19 |
|||
Hbond acc |
8 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Trastuzumab-Example 5 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.01165 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
On the day of administration, HER2 targeted ADC and HER2 were prepared at a 10 fold ratio in standard growth medium. Add the prepared targeted ADC treatment to cells to obtain a final concentration of 3.81e-5nM to 100nM and a final volume of 50uL/well. Each drug concentration is tested in quadruplicate. On the same day, the cell viability of untreated cells at the time of administration was evaluated by adding 25 u L of CellTiter (ProMag catalog number G7573), a reagent for lysing cells and measuring total adenosine triphosphate (ATP) content. Incubate the plate at room temperature for 10 minutes to stabilize the luminescence signal before reading. Use luminous readingThe PHERAstar FSX ELISA reader (BMG Labtech) was used to measure the luminescence signals of all plates. This signal represents the cell viability of untreated cells on the day of administration or day 0.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.0408 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
On the day of administration, HER2 targeted ADC and HER2 were prepared at a 10 fold ratio in standard growth medium. Add the prepared targeted ADC treatment to cells to obtain a final concentration of 3.81e-5nM to 100nM and a final volume of 50uL/well. Each drug concentration is tested in quadruplicate. On the same day, the cell viability of untreated cells at the time of administration was evaluated by adding 25 u L of CellTiter (ProMag catalog number G7573), a reagent for lysing cells and measuring total adenosine triphosphate (ATP) content. Incubate the plate at room temperature for 10 minutes to stabilize the luminescence signal before reading. Use luminous readingThe PHERAstar FSX ELISA reader (BMG Labtech) was used to measure the luminescence signals of all plates. This signal represents the cell viability of untreated cells on the day of administration or day 0.
Click to Show/Hide
|
||||
| In Vitro Model | Breast carcinoma | ZR-75-30 cells | CVCL_1661 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.04618 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
On the day of administration, HER2 targeted ADC and HER2 were prepared at a 10 fold ratio in standard growth medium. Add the prepared targeted ADC treatment to cells to obtain a final concentration of 3.81e-5nM to 100nM and a final volume of 50uL/well. Each drug concentration is tested in quadruplicate. On the same day, the cell viability of untreated cells at the time of administration was evaluated by adding 25 u L of CellTiter (ProMag catalog number G7573), a reagent for lysing cells and measuring total adenosine triphosphate (ATP) content. Incubate the plate at room temperature for 10 minutes to stabilize the luminescence signal before reading. Use luminous readingThe PHERAstar FSX ELISA reader (BMG Labtech) was used to measure the luminescence signals of all plates. This signal represents the cell viability of untreated cells on the day of administration or day 0.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma of no special type | UACC812 cells | CVCL_1781 | ||